Who are Candel Therapeutics, Inc.'s main suppliers?

Candel Therapeutics, Inc. (CADL) key suppliers include: Genelux Corporation. View the full supplier network at chainsifter.com/chain/CADL.

Who are Candel Therapeutics, Inc.'s major customers?

Candel Therapeutics, Inc. (CADL) key customers include: VENTAGEN, Genelux Corporation, Theriva Biologics, Inc., Trinity Capital Inc., Trinity Capital Inc. and 4 more. View the full customer network at chainsifter.com/chain/CADL.

What sector is Candel Therapeutics, Inc. in?

Candel Therapeutics, Inc. (CADL) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Candel Therapeutics, Inc. (CADL) Suppliers & Customers

1Suppliers

9Customers

2Debt Items

19Related Chains

Source-Backed Evidence Depth

Candel Therapeutics, Inc. (CADL) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

13Total relationships

1Distinct source URLs

4High confidence

0.746Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Candel Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
GNLX	Genelux Corporation	72%	Reciprocal relationship from GNLX graph: g process and had to demonstrate analytical comparability to the FDA in order to use Olvi-Vec manufactured by this process in our ongoing Phase 3 PRROC trial.…

Candel Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
VENTAGEN	VENTAGEN	92%	Ventagen agreed to purchase from the Company all manufactured product that is required for clinical or commercial purposes at a price of cost plus 25 % of the wholesale price of the approved product
GNLX	Genelux Corporation	72%	Reciprocal relationship from GNLX graph: ials between batches from a single supplier or between suppliers; ● the possible breach by our third-party suppliers and service providers of our agreements w…
TOVX	Theriva Biologics, Inc.	72%	Reciprocal relationship from TOVX graph: prescribe legally available drugs for off-label uses, drugs may be marketed only for the approved indications and in accordance with the provisions of the app…
TRIN	Trinity Capital Inc.	72%	from such transactions. In addition, in February 2022, we borrowed $20.0 million under the four-year loan and security agreement (the SVB Loan Agreement) with Silicon Valley Bank (SVB). On October 14…
TRIN	Trinity Capital Inc.	72%	Reciprocal relationship from TRIN graph: Reciprocal relationship from CADL graph: from such transactions. In addition, in February 2022, we borrowed $20.0 million under the four-year loan and securit…
DELAWARE-GENERAL-CORPORATION	DELAWARE-GENERAL-CORPORATION	62%	ry review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the appli…
NC-INCORPORATED	NC-INCORPORATED	62%	thereunder; • our ability to enter into agreements with contract development and manufacturing organizations (CDMOs) for the development, clinical manufacture and commercial manufacture of our produc…
PBM-CAPITAL-GROUP-LLC	PBM-CAPITAL-GROUP-LLC	62%	ry review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the appli…
Q-EMERGING-GROWTH-COMPANY	Q-EMERGING-GROWTH-COMPANY	62%	; • the scope, progress, results, and costs of any product candidates that we may derive from our HSV-based platform or with collaborators; • the costs of preparing, filing and prosecuting patent app…

Candel Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
CADL-DEBT	Debt stack $1.7M	90%	Market cache reports total debt of $1.7M.
CADL-DEBT-8450	Warrants outstanding: 430000	90%	xbrl warrant detail from xbrl 2025-12-31.

Candel Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Candel Therapeutics, Inc..

Candel Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
CADL-OWNER-FMR-LLC	FMR LLC	90%	13F overlay lists FMR LLC as top holder; 115 tracked holders.

Candel Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
TSHA	Taysha Gene Therapies, Inc.	100.00	2
SI	Shoulder Innovations, Inc.	100.00	2
TOVX	Theriva Biologics, Inc.	100.00	1	['customer']
RPID	Rapid Micro Biosystems, Inc.	100.00	2
GNLX	Genelux Corporation	100.00	1	['customer', 'supplier']
BMY	Bristol-Myers Squibb Company	50.00	2
BMYMP	Bristol-Myers Squibb Co	50.00	2
ONCY	Oncolytics Biotech Inc.	50.00	2
MCRB	Seres Therapeutics, Inc.	50.00	2
LLY	Eli Lilly and Company	50.00	2
CORZ	Core Scientific, Inc.	50.00	2
CELG-RI	BRISTOL MYERS SQUIBB CO	50.00	2
REGN	Regeneron Pharmaceuticals, Inc.	50.00	2
CGON	CG Oncology, Inc.	50.00	2
CLDWW	Calidi Biotherapeutics, Inc.	50.00	2
REPL	Replimune Group, Inc.	50.00	2
IOVA	Iovance Biotherapeutics, Inc.	50.00	2
JNJ	Johnson & Johnson	50.00	2
TRIN	Trinity Capital Inc.	38.88	1	['customer']

Candel Therapeutics, Inc. Supply Chain